Sanofi-Aventis KK and Astellas Pharma, Inc., both headquartered in
Tokyo, Japan, will discontinue their marketing alliance for Ketek 300-mg
tablets (telithromycin). Sanofi-Aventis will solely market the
treatment.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Copyright ©
Entrepreneur.com, Inc. All rights reserved.
Privacy Policy